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Summary Between January 1977 and January 1988, 19 patients with non-Hodgkin's lymphoma (NHL)
involving the ileocaecal region were cared for by the CRC Wessex Medical Oncology Unit. Fifteen of these
patients had primary ileocaecal NHL (stages IE or IIE) and four had secondary involvement of this region
(stage IV). The commonest clinical presentation was with abdominal pain and a palpable mass in the right
iliac fossa. Bulky (>10cm) disease was a particularly common feature, and complete surgical removal was
possible in only seven patients. All patients had intermediate (18) or high grade (one) NHL using the Working
Formulation. The commonest histological subtype was diffuse large cell. Seventeen patients received post-
operative therapy, comprising local radiotherapy in one and combination chemotherapy in the remaining 16.
Eleven of the 19 patients remain disease-free 6-60 months from diagnosis. Because of the high incidence of
bulky disease at this site, postoperative therapy may be indicated, even for patients with apparently
completely excised stage I disease.
Non-Hodgkin's lymphoma (NHL) of the gastrointestinal
(GI) tract accounts for about 1-2% of all cases of GI
malignancy (Burgess et al., 1971; Freeman et al., 1972). It
comprises 1-7% of all malignancies of the stomach (Burgess
et al., 1971; Freeman et al., 1972; Fleming et al., 1982), 20%
of those in the small bowel and less than 0.5% of those in
the large bowel (Cutler et al., 1975). However, 40% of all
primary extranodal NHL is of GI origin (Burgess et al.,
1971). Secondary involvement of the GI tract by NHL is
also very common, although its incidence is much more
difficult to ascertain.
Although involvement of the terminal ileum and caecum
has been documented in American Burkitt's lymphoma
(Arseneau et al., 1975), in some large series of patients with
GI NHL (Leewin et al., 1978; Herrman et al., 1980), in
patients with immunosuppression related to drugs used for
organ transplantation (Starzl et al., 1984) and in patients
developing NHL after treatment for Hodgkin's disease
(Krikorian et al., 1979), no reports have specifically
addressed this entity in adults. We report here our experience
of the treatment of NHL of the ileocaecal region, including
primary and secondary cases, with particular reference to the
clinical features at presentation and to outcome. We believe
this to be the first report to describe specifically the outcome
of treatment for a group of adult patients with ileocaecal
NHL.
Patients and methods
The records of all patients with non-Hodkgin's lymphoma
managed by the CRC Wessex Medical Oncology Unit
between January 1977 and May 1988 were reviewed and
patients with gastrointestinal involvement were identified.
From these records, patients with ileocaecal involvement at
presentation were selected for further review. An additional
three patients, whose initial post-surgical management was
carried out at another centre, but who later came under our
care, were also included. Cases of ileocaecal lymphoma were
classified as primary or secondary according to the criteria
of Dawson et al. (1961). Thus patients with (i) no
enlargement of peripheral or mediastinal lymph nodes,
(ii) normal white cell count, (iii) predominant GI tract lesions
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and (iv) no liver or splenic involvement were defined as
primary cases, and all others as secondary cases.
Diagnostic laparotomy had been performed prior to
referral in all patients. Surgical procedures differed and are
listed in the Results section. Routine staging procedures
included a full blood count, erythrocyte sedimentation rate,
lymphocyte immunophenotype, serum biochemistry profile,
serum lactate dehydrogenase, serum immunoglobulins,
urinary Bence-Jones protein excretion, chest X-ray,
abdominal ultrasound, bipedal lymphangiogram and/or
abdominal computed tomography and unilateral bone
marrow aspirate and trephine biopsy. A liver biopsy was
performed at the initial laparotomy in those patients in
whom a diagnosis of lymphoma was suspected by the
surgeon.
Patients were staged according to the Ann Arbor
(Carbone et al., 1971) staging system. Histological review of
all biopsy material was performed by one of us (D.H.W.),
and all specimens were classified according to the Working
Formulation (Non-Hodgkin's Lymphoma Pathologic
Classification Project, 1982).
Those patients who received chemotherapy were treated
with one of four combination regimens according to the
treatment protocols in use in the unit at the time of
presentation. These were CHOP (Armitage et al., 1982),
CHOP-PEPA (Mead et al., 1987), CVP (Luce et al., 1971)
and the Southampton NH4 protocol (etoposide
150 mgm 2i.v. day 1, doxorubicin 35mgm 2i.v. day 1,
cyclophosphamide 300mgm 2i.v. day 1, methotrexate
100mgm-2 i.v. day 8, (with leucovorin rescue), vincristine
1.4mgm-2 i.v. day 8, bleomycin lOmgm-2 i.v. day 8, six
cycles at 14-day intervals with prednisolone 50mg daily for 4
weeks, and then on alternate days for 8 further weeks).
The patient who received radiotherapy was treated with
3,500cGy delivered in 14 fractions of 250cGy to the
ileocaecal region and to the draining lymph nodes.
Patients were evaluated for response 1 month after the
completion of chemotherapy and radiotherapy, or 1 month
after surgery for those patients who received no post-surgical
therapy. Response criteria were as follows. Complete
remission (CR) is complete disappearance of measurable
disease. Partial remission (PR) is a decrease of more than
50% of the sum of the products of the perpendicular
diameters of the measurable disease. No response (NR) is
less than 50% reduction of the sum of the products of the
perpendicular diameter of the measurable disease.
Progressive disease (PD) is an increase in size of measurable
disease, or appearance of disease at new sites.
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Results
During the specified period a total of 16 cases of non-
Hodgkin's lymphoma involving the ileocaecal region were
identified from the patients managed entirely by this unit. Of
these, 13 cases were identified as primary ileocaecal
lymphoma. An additional three cases (two primary and one
secondary) initially managed at other centres were included,
In the same period a total of 59 cases of primary GI
lymphoma at all sites have been managed by the unit. Thus,
for cases managed solely in this centre, ileocaecal comprised
22% of all primary GI NHL.
The median age at presentation for all patients was 62
years (range 27-83). Twelve patients were female and seven
were male. Other characteristics are summarised in Table I.
None of the patients demonstrated features of the acquired
immunodeficiency syndrome.
All patients initially presented to a general surgeon. The
symptoms and signs at presentatiuon are shown in Table II.
The duration of symptoms prior to diagnosis ranged from 1
week to 6 months (median 2 months). The most common
features were abdominal pain, usually localised to the right
iliac fossa, with an associated palpable right iliac fossa mass.
Diarrhoea and weight loss were common accompanying
symptoms. Three patients presented as acute surgical
emergencies. Two of these had bowel obstruction and the
third, a perforated terminal ileum.
The most common preoperative diagnosis was carcinoma
of the caecum. Only three patients underwent gastro-
intestinal investigations before laparotomy. Two patients had
a barium enema which showed a stricture in the terminal
ileum in both cases. The third had a colonoscopy which
revealed a mass in the caecum. Biopsy specimens from this
mass showed no evidence of malignant disease.
Findings at surgery
A laparotomy was performed in all cases, and operative
specimens provided the diagnostic tissue in all but one. All
patients had masses invading the terminal ileum and caecum.
In 16 cases these masses were more than 5cm in diameter
and 13 of these were greater than 10cm. Four patients had
associated smaller deposits in the terminal ileum but only
one had evidence of disease elsewhere in the small intestine,
with multiple deposits throughout the entire length of the
jejunum and ileum, in a pattern similar to that previously
described by several authors (Lewin et al., 1978; Dawson et
al., 1961; Weingrad et al., 1982; Sheehan et al., 1971).
Mesenteric lymph nodes were enlarged in 12 cases, being
more than 5cm in diameter in four of these. These nodes
were biopsied in 1I of the 12 cases and found to be involved
with lymphoma in every case. Para-aortic nodal enlargement
was present in six cases, of whom one had extra-abdominal
disease. In all six cases, subsequent lymphangiography or
computed tomography showed para-aortic nodal
enlargement consistent with lymphomatous infiltration.
Biopsies of para-aortic lymph nodes were performed in only
two patients and showed lymphoma in both.
Surgical procedures and morbidity
The surgical procedures undertaken are listed in Table III.
Right hemicolectomy with resection of the terminal ileum
was the commonest procedure. Mesenteric lymph nodes were
excised in only three cases, although they were biopsied more
frequently (see above). Three of the four patients with
stage IV disease had unresectable intra-abdominal tumours.
The fourth patient with stage IV disease apparently had a
complete resection of all macroscopic disease, but was found
to have liver involvement on the basis of a wedge biopsy
performed at the original laparotomy.
The most frequent postoperative complication was
diarrhoea, with frequent passage of loose, watery stools. This
was experienced by most patients undergoing right hemi-
Table I Patient characteristics
Primary Secondary
cases cases Total
Number of patients 15 4 19
Stage IE 4 - 4
IIE 11 - 11
IV - 4 4
B symptoms - 3 3
Preoperative disease bulk<5 cm 3 - 3
>5cm 12 4 16
Histology (working formulation)
DLC 12 2 14
DM 1 - 1
DSC 2 1 3
Burkitt - 1 1
DLC, diffuse large cell; DM, diffuse mixed small and large cell;
DSC, diffuse predominantly small cleaved cell.
Table II Symptoms and signs at presentation
No. of
Symptom/sign patients
Abdominal pain 18
Diarrhoea 8
Weight loss over 10% of initial body weight 8
Blood loss with anaemia (obvious or occult) 6
Nausea and vomiting 3
B symptoms (other than weight loss) 3
Peripheral lymphadenopathy 3
Palpable right iliac fossa mass 16
Intestinal obstruction 2
Bowel perforation I
Table III Surgical procedures undertaken in patients
ileocaecal NHL
with
Procedure No.
Right hemicolectomy and resection of terminal ileum 13
Right hemicolectomy, resection of terminal ileum and
excision of mesenteric lymph nodes 3
Biopsy of mass only 2
Ileo-transverse anastomosis 1
Clinical or radiological evidence of residual disease
after surgery (primary cases only) 8/15
colectomy, and has been persistent in some, although
controllable. Patients who have had terminal ileal resections
have been given intermittent vitamin B12'
Pathology
The histological subtypes of the lymphomas are shown in
Table I. Diffuse large cell lymphoma was the commonest
subtype (14), followed by diffuse small cleaved cell (3). Of
those diagnosed as diffuse small cleaved cell, one showed the
gross and histological features of multiple lymphomatous
polyposis (Sheehan et al., 1971). No cases of low grade
lymphoma were seen.
Primary ileocaecal lymphoma
Complete excision of all macroscopic disease was possible in
seven of the 15 patients with primary ileocaecal involvement.
No evidence of disease in other sites was found in any of
these patients after formal staging. Of these seven patients,
five received adjuvant therapy, comprising local radiotherapy
in one, and combination chemotherapy in four (CHOP in
two, CHOP/PEPA in one and CVP in one). Three of those
five patients are alive with no evidence of disease. One was368 J.W. SWEETENHAM et al.
treated with six cycles of CVP, achieving a CR, but died of
disseminated bladder cancer 43 months after presentation,
with no evidence of lymphoma at post-mortem. The other
died of sepsis associated with neutropenia shortly after
receiving the first cycle of chemotherapy with CHOP.
One of the two patients who received no adjuvant therapy
remains well with no evidence of disease, one year after
laparotomy, and the other relapsed 11 months after the
initial diagnosis but has achieved a complete remission with
CHOP chemotherapy.
Mesenteric or para-aortic nodes were the commonest sites
of residual unresected disease after laparotomy. The eight
patients with residual disease received combination
chemotherapy with CHOP or CHOP/PEPA. Seven of these
achieved complete remissions and one died of sepsis after
two cycles of CHOP chemotherapy and was therefore
inevaluable for response. Two of the seven complete
responders have relapsed in para-aortic lymph nodes within
3 months of completing chemotherapy. Both responded
briefly to further combination chemotherapy, but eventually
died of disseminated disease. Complete remission has been
maintained in the remaining five patients at 7, 37, 52, 53 and
54 months after the completion of chemotherapy.
Bowel perforation did not occur in any of these patients
following chemotherapy, even in the case where residual
disease was known to be present in the small bowel.
As is shown in Table IV, the four patients with stage IE
disease remain alive and disease-free at 13, 57, 58 and 60
months from diagnosis. For those with stage IIE disease, six
of 11 remain disease-free 6-60 months from diagnosis. The
other stage II patients have died, four of disease and one
from an unrelated cause.
Table IV Outcome by stage, histology, and
disease bulk for patients with ileocaecal lymphoma
Statusa
(primary cases
in parentheses)
No. AO DO D+
Stage
IE 4 4 - -
IIE 11 6 1 4
IV 4 1 - 3
Histology
DLC 14 (12) 10 (9) 1 (1) 3 (2)
DM 1 (1) 1 (1) - -
DSC 3 (2) - - 3 (2)
Burkitts 1 (-) - 1
Disease bulk
<5cm 3 (2) 2 (2) - 1(-)
>5cm 16 (13) 9 (8) 1 (1) 6 (4)
'A', alive with no evidence of disease; Do, dead
with no evidence of disease; D+, dead of disease.
See also footnote to Table I.
The outcome by bulk of disease at presentation is also
shown in Table IV, as is the outcome by histological
subtype. The majority of patients had bulky disease at
presentation. The two patients with non-bulky disease, both
of whom had complete resections, remain disease-free. Nine
of the 12 patients with diffuse large cell lymphoma remain
disease-free 6-60 months after completion of chemotherapy.
The two patients with diffuse small cleaved cell subtype have
both died of disease.
Secondary ileocaecal lymphoma
The four patients with secondary ileocaecal lymphoma, all of
whom had stage IV disease, all presented with prominent GI
symptoms. None of them had peripheral lymphadenopathy
at presentation. Three of these four had infiltration of the
bone marrow and the other had liver involvement but no
extra-abdominal disease. The outcome for these patients is
summarised in Table IV.
The patient who had disease confined to the abdomen was
treated with the Southampton NH4 regimen and remains in
complete remission 11 months after completing chemo-
therapy. Two patients received CHOP chemotherapy and
achieved partial responses, but both relapsed within 4
months of completing chemotherapy. Both died of
lymphoma within 10 months of diagnosis. The fourth patient
was in extremis at the time of presentation to our unit, and
treatment was not given.
Discussion
This report summarises the experience of our unit in the
management of ileocaecal non-Hodgkin's lymphoma.
Because of the rarity of NHL involving this site, the number
of cases is small and conclusions regarding management are
therefore difficult to reach.
We are unaware of any previous reports that have
specifically addressed the clinical features and outcome for
this disease entity in a group of adult patients. Most large
retrospective series have shown the stomach to be the
commonest site for GI NHL, comprising 40-45% of all
cases of primary GI involvement (Lewin et al., 1978;
Herrman et al., 1980; Dragosics et al., 1985). Two large
series document ileocaecal lymphoma in 13 of 117 (11%)
(Lewin et al., 1978) and 14 of 71 (20%) (Herrman et al.,
1980) patients with primary GI NHL, a figure comparable to
our own (22%). The two reports mentioned above, unlike
ours, include paediatric cases, with most cases less than 16
years old. A marked male predominance was recorded in
both studies. Our experience is confined to adults, in whom
this disease occurs most commonly in the age group 40-70
years, as with most other GI lymphomas. No male
predominance was seen.
The commonest presenting symptom was abdominal pain.
Diarrhoea, weight loss and blood loss were also common,
although acute surgical emergencies were a surprisingly rare
presenting phenomenon. Intussusception is reported as a
frequent mode of presentation for ileocaecal NHL,
particularly in the paediatric group, but was not seen in any
of our patients. It is well established that prior GI
pathology, especially coeliac disease, is associated with small
intestinal GI NHL (Mead et al., 1987; Gough et al., 1962);
Cooper et al., 1980), but no such history was given by any
of our patients.
The physical findings at presentation in our patients were
at variance with previous reports. Although palpable
abdominal masses are a feature of childhood ileocaecal
NHL, they have been thought to be less common in adults,
possibly because abdominal masses are less easy to palpate
in this age group. However, 84% of our patients had a
palpable right iliac fossa mass.
Peripheral lymph nodes were present in only one patient
in our series throughout the whole course of the disease, and
then only in the terminal stages. Consequently, a
preoperative diagnosis of carcinoma of the caecum was most
often made. This experience contrasts markedly with that of
Hande et al. (1978), from the National Cancer Institute, who
found peripheral lymphadenopathy in 16 of 18 patients with
diffuse histiocytic lymphoma of the GI tract, but is
consistent with the Lewin et al. (1978) findings of peripheral
nodes in only five of 117 cases of all histological subtypes.
However, in view of our very small number of stage IV
cases, no direct comparisons can be made. The most striking
feature of the operative findings was the frequency of bulky
disease, with most masses over 5cm in diameter and many
over 10cm. This is not a typical feature of GI lymphoma at
other sites. Complete surgical resection was possible in only
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The majority of cases were classified histologically as
intermediate grade (Working Formulation). Only one was
high grade. This is in marked contrast to the previously
published cases of ileocaecal NHL, which have typically been
of high grade subtype (Arseneau et al., 1975; Lewin et al.,
1978).
The factors influencing prognosis of GI NHL have been
examined in a number of studies in an attempt to produce
consistent treatment recommendations. These studies have
included disease at all levels of the GI tract, and have
comprised mainly (or entirely) gastric lymphoma (Lewin et
al., 1978; Dragosics et al., 1985; Shepherd et al., 1988).
Clearly the number of cases in our series makes detailed
analysis ofprognostic factors impossible. There is a trend for
a poorer outcome with more advanced stage. All four
stage IE patients remain disease-free whereas three of four
with stage IV disease have died, the surviving patient having
had no extra-abdominal spread.
It is not possible to comment on the influence of disease
bulk since only two patients with primary disease had masses
less than 5cm. No obvious effect of complete resection on
outcome is evident. Similarly, the small numbers make
assessment of the role of histological subtype impossible.
In patients with primary ileocaecal NHL, all but two
received postoperative therapy, even in the absence of any
residual disease. We cannot therefore comment on the effect
of treatment on outcome, although one of the two patients
who had no adjuvant therapy after apparently complete
excision of disease developed disease recurrence and was
salvaged with combination chemotherapy.
The overall outcome for cases of primary ileocaecal NHL
was good, with 67% alive and disease-free at 6-60 months
from diagnosis. This figure is particularly encouraging in
view of the large number of patients with bulky disease.
Because of its rarity, specific treatment recommendations
for ileocaecal NHL do not exist. Clearly, for secondary cases
with stage III or IV disease, combination chemotherapy is
appropriate. For those patients with incompletely excised
stage I or II disease, we similarly recommend that
combination chemotherapy should be given. The most
appropriate postoperative management of patients with
completely excised stage I or II disease is less clear. For
NHL in other sites in the GI tract, particularly in the
stomach, complete surgical excision is generally considered
to be adequate therapy. However, a striking feature of the
cases in this series has been the frequency of bulky disease,
which is far in excess of that reported for NHL at other GI
tract sites.
For this reason, we believe that adjuvant therapy for
completely excised stage I or II disease should be considered,
especially if the original disease was bulky. For those cases
with non-bulky, completely excised disease, further therapy
may not be required.
We wish to thank Dr P.F. Golding for allowing us to report cases
under her care and Mrs J. Boston for typing the manuscript.
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